Siplizumab is a monoclonal antibody that targets the CD2 receptor, primarily involved in T-cell activation and proliferation. It is designed to modulate the immune response, making it particularly relevant in the treatment of autoimmune diseases and organ transplant rejection. As a humanized IgG1 kappa antibody, Siplizumab exhibits high specificity and affinity for its target, which helps in minimizing off-target effects. The mechanism of action involves blocking the interaction between CD2 and its ligands, thereby inhibiting T-cell activation and proliferation. This characteristic makes Siplizumab a potential therapeutic agent in conditions where T-cell mediated immunity is detrimental. The substance is typically administered via injection, and its pharmacokinetics can be influenced by factors such as dosage, administration route, and patient-specific variables. Safety and efficacy profiles are established through clinical trials, and like other monoclonal antibodies, Siplizumab may have associated side effects, including infusion reactions and increased susceptibility to infections. Overall, Siplizumab represents a targeted approach in immunotherapy, reflecting advancements in biopharmaceutical development.

Siplizumab

288392-69-8: Siplizumab is a monoclonal antibody that targets the CD2 receptor, primarily involved in T-cell activation and proliferation. It is designed to modulate the immune response, making it particularly relevant in the treatment of autoimmune diseases and organ transplant rejection. As a humanized IgG1 kappa antibody, Siplizumab exhibits high specificity and affinity for its target, which helps in minimizing off-target effects. The mechanism of action involves blocking the interaction between CD2 and its ligands, thereby inhibiting T-cell activation and proliferation. This characteristic makes Siplizumab a potential therapeutic agent in conditions where T-cell mediated immunity is detrimental. The substance is typically administered via injection, and its pharmacokinetics can be influenced by factors such as dosage, administration route, and patient-specific variables. Safety and efficacy profiles are established through clinical trials, and like other monoclonal antibodies, Siplizumab may have associated side effects, including infusion reactions and increased susceptibility to infections. Overall, Siplizumab represents a targeted approach in immunotherapy, reflecting advancements in biopharmaceutical development.

Siplizumab (MEDI-507), an IgG1 antibody targeting CD2, depletes T cells, may treat psoriasis.

Anti-CD2 monoclonal antibody, potential psoriasis treatment, immunomodulatory effects

CAS 288392-69-8

Siplizumab

Siplizumab

Ref: 54-BUP20199

Siplizumab

Ref: TM-T77170

Siplizumab

Ref: 3D-CLA1070